696 related articles for article (PubMed ID: 22149003)
1. Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.
Honda H; Hosaka N; Aoshima Y; Hirai Y; Michihata T; Akizawa T
Clin Exp Hypertens; 2012; 34(1):17-23. PubMed ID: 22149003
[TBL] [Abstract][Full Text] [Related]
2. Olmesartan medoxomil treatment is associated with decreased plasma B-type natriuretic peptide levels in patients on hemodialysis.
Suzuki R; Honda H; Niikura K; Akizawa T
Clin Exp Hypertens; 2012; 34(2):125-31. PubMed ID: 21967019
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels and dietary intake of the advanced glycation end-product marker carboxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: a pilot study.
Piroddi M; Palazzetti I; Quintaliani G; Pilolli F; Montaldi M; Valentina V; Libetta C; Galli F
J Ren Nutr; 2011 Jul; 21(4):329-39. PubMed ID: 21193322
[TBL] [Abstract][Full Text] [Related]
5. Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.
Kawai T; Takei I; Shimada A; Hirata T; Tanaka K; Saisho Y; Irie J; Horimai C; Matsumoto H; Itoh H
Clin Drug Investig; 2011; 31(4):237-45. PubMed ID: 21184621
[TBL] [Abstract][Full Text] [Related]
6. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
Nakayama S; Watada H; Mita T; Ikeda F; Shimizu T; Uchino H; Fujitani Y; Hirose T; Kawamori R
Hypertens Res; 2008 Jan; 31(1):7-13. PubMed ID: 18360012
[TBL] [Abstract][Full Text] [Related]
7. Effect of olmesartan on oxidative stress in hemodialysis patients.
Kadowaki D; Anraku M; Tasaki Y; Kitamura K; Wakamatsu S; Tomita K; Gebicki JM; Maruyama T; Otagiri M
Hypertens Res; 2007 May; 30(5):395-402. PubMed ID: 17587751
[TBL] [Abstract][Full Text] [Related]
8. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
Engelen L; Persson F; Ferreira I; Rossing P; Hovind P; Teerlink T; Stehouwer CD; Parving HH; Schalkwijk CG
Nephrol Dial Transplant; 2011 Nov; 26(11):3573-7. PubMed ID: 21385863
[TBL] [Abstract][Full Text] [Related]
9. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Nangaku M; Miyata T; Sada T; Mizuno M; Inagi R; Ueda Y; Ishikawa N; Yuzawa H; Koike H; van Ypersele de Strihou C; Kurokawa K
J Am Soc Nephrol; 2003 May; 14(5):1212-22. PubMed ID: 12707391
[TBL] [Abstract][Full Text] [Related]
10. Are advanced glycation end products cardiovascular risk factors in patients with CRF?
Stein G; Busch M; Müller A; Wendt T; Franke C; Niwa T; Franke S
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S52-6. PubMed ID: 12612953
[TBL] [Abstract][Full Text] [Related]
11. The influence of gender, weight, height and BMI on pentosidine concentrations in plasma of hemodialyzed patients.
Slowick-Zylka D; Safranow K; Dziedziejko V; Dutkiewicz G; Ciechanowski K; Chlubek D
J Nephrol; 2006; 19(1):65-9. PubMed ID: 16523428
[TBL] [Abstract][Full Text] [Related]
12. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
Ishii M
Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
[TBL] [Abstract][Full Text] [Related]
13. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
14. Effect of protein leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels.
Tessitore N; Lapolla A; Aricò NC; Poli A; Gammaro L; Bassi A; Bedogna V; Corgnati A; Reitano R; Fedele D; Lupo A
J Nephrol; 2004; 17(5):707-14. PubMed ID: 15593039
[TBL] [Abstract][Full Text] [Related]
15. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms for the formation of glycoxidation products in end-stage renal disease.
Weiss MF; Erhard P; Kader-Attia FA; Wu YC; Deoreo PB; Araki A; Glomb MA; Monnier VM
Kidney Int; 2000 Jun; 57(6):2571-85. PubMed ID: 10844627
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
[TBL] [Abstract][Full Text] [Related]
18. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
19. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Daikuhara H; Fukunaga K; Ohshima T
Drug Des Devel Ther; 2014; 8():219-26. PubMed ID: 24600204
[TBL] [Abstract][Full Text] [Related]
20. Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites.
Klemm A; Franke C; Busch M; Müller A; Franke S; Lang D; Passlick-Deetjen J; Stein G
Clin Nephrol; 2004 Mar; 61(3):191-7. PubMed ID: 15077870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
